Serum Hepatocyte Growth Factor and Interleukin-6 Are Effective Prognostic Markers for Non-small Cell Lung Cancer
Anticancer Research, 07/27/2012
Ujiie H et al. – The levels of hepatocyte growth factor (HGF) and interleukin–6 (IL–6) in serum could be useful prognostic indicators of the survival of patients with stage III NSCLC undergoing surgery and chemotherapy.Methods
- The authors obtained preoperative serum from 109 patients, and measured the levels of hepatocyte growth factor (HGF), interleukin-6 (IL-6), and nicotinamide N-methytransferase (NNMT) in the sera.
- The median HGF and IL-6 contents were 860pg/ml and 2.7 pg/ml, respectively.
- Analysis of survival curves indicated that an HGF or IL-6 level higher than the median was associated with poor overall survival (HGF, p=0.019; IL-6, p=0.002).
- In addition, they analyzed stage III lung cancer alone.
- Higher HGF and IL-6 levels were associated with poor overall survival (HGF, p=0.016; IL-6, p=0.013).
- Disease-free survival was not statistically significantly affected by these cytokine contents.
- The tumor status (pT factor) and nodal status (pN factor) were not associated with the survival of stage III patients.